Please assess the completion status of the following clinical trial:

Trial Title: Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* PRE-REGISTRATION INCLUSION:~* Individuals with a clinical diagnosis fibrosis or cirrhosis of the liver (no more than Child-Pugh classification A; Child-Pugh-Turcotte score of 6 or less) who have:~  * An indication for surgical liver resection, OR~ * A clinical liver biopsy (with research tissue specimens available for analysis) =\< 3 months prior to pre-registration~* Willingness to discontinue smoking during the study two weeks prior to beginning the study and willingness to not smoke while taking study medication~* Not pregnant or breast feeding. Note: The effects of erlotinib (Tarceva) on the developing human fetus at the recommended therapeutic dose are unknown; for this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately.~* Willingness to use adequate contraception to avoid pregnancy or impregnation until 2 weeks after discontinuing study agent~* Willingness to provide mandatory blood specimens~* Able to undergo:~  * Percutaneous or transjugular biopsy of cirrhotic liver at least 7 days prior to liver resection (surgical cohort), OR~ * A biopsy of the cirrhotic liver (non-surgical cohort)~* Willingness to authorize collection of tissue from surgically-resected liver or clinical liver biopsy for analyses~* Ability to understand and the willingness to sign a written informed consent document~* REGISTRATION INCLUSION:~* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1~* International normalized ratio (INR) =\< 1.5~* Platelets \>= 50 B/L (10\^9/L)~* Total bilirubin =\< 3 x institutional upper limit of normal (ULN)~* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 5 x institutional ULN~* Creatinine =\< 1.5 x institutional ULN~* Non-surgical cohort only: positive phospho-EGFR assessment (\>= 100 stained pixels) from tissue obtained from previous clinical liver biopsy~* Pre-intervention biopsy sample collected~Exclusion Criteria:~* PRE-REGISTRATION EXCLUSION:~* Any prior treatment with erlotinib or other agent whose primary mechanism of action is known to inhibit EGFR~* Participants with a known diagnosis of human immunodeficiency virus (HIV); Note: an HIV screening test does not have to be performed to evaluate this criterion~* Participants who regularly (\>= 2 times per week) use drugs that alter the pH of the gastrointestinal (GI) tract, such as proton pump inhibitors (PPI) and antacids; exceptions: individuals who use prescription PPIs and have approval from their primary health care provider to discontinue for the duration of clinical trial participation may be enrolled; an alternate drug to control gastroesophageal reflux disease (GERD)/peptic ulcer disease (PUD) symptoms will be suggested~* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements~* Use of potent CYP3A4 inhibitors, such as ketoconazole, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, voriconazole, and grapefruit or grapefruit juice~* Use of CYP3A4 inducers such as rifampicin, rifabutin, rifapentine, phenytoin, carbamazepine, phenobarbital, and St. John's wort~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to erlotinib (Tarceva)~* Participants who cannot have their warfarin, Lovenox, Plavix, or other comparable medications held for percutaneous or transjugular liver biopsy and surgery if so indicated~* Non-surgical cohort only: pathology report from clinical liver biopsy (=\< 3 months prior to pre-registration) demonstrates no histologic abnormalities associated with chronic hepatitis, steatohepatitis, fibrosis, or cirrhosis~* REGISTRATION EXCLUSION:~* Receiving any other investigational agents =\< 6 months prior to registration~* Surgical cohort (cohort A only): percutaneous or transjugular biopsy incomplete or not performed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prevention (erlotinib hydrochloride) (Type: EXPERIMENTAL): Patients receive erlotinib hydrochloride PO QD for 7 days (depending on the date of surgery, treatment range may be 5-14 days).

Based on this trial design, predict the completion outcome and termination type (if applicable).